Minimum Requirements for Reporting Fecal Microbiota Transplant Trial

Shirin Moossavi, Faraz Bishehsari, Reza Ansari, Homayoon Vahedi, Siavosh Nasseri-Moghaddam, Shahin Merat, Iradj Sobhani, Ali Keshavarzian, Reza Malekzadeh

Abstract


Fecal microbiota transplant (FMT) research trials are growing in diverse intestinal and extraintestinal conditions that are thought to be either caused or correlated with gut microbiota dysbiosis. Although, the mechanism by which the microbiota results in disease initiation or progression is not fully understood, it is speculated that restoring the symbiosis by FMT could have therapeutic benefits.


Keywords


Fecal Microbiota;Dysbiosis; Therapeutic benefits

Full Text:

PDF


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.